tldrdailynews.com logo

Lilly China deals, Akeso bispecific advance, ASCO updates reshape biotech

1 min read
Source: statnews.com
Lilly China deals, Akeso bispecific advance, ASCO updates reshape biotech
Photo: statnews.com
TL;DR

The Readout highlights Eli Lilly’s two China deals, Akeso’s promising lung cancer bispecific, and ASCO-driven updates on pancreatic cancer therapies (including daraxonrasib results), alongside chatter about a high-profile Chinese lung cancer therapy and a broader regulatory debate over an old peptide, illustrating how deals, trials, and policy are shaping biotech today.

Topics:top-newsbiotech#akeso#asco#biotech#china-deals#eli-lilly#pancreatic-cancer
Share this article
  1. A turning point for pancreatic cancer patients  statnews.com
  2. After new drug’s ‘unprecedented’ results for pancreatic cancer, doctors look at other uses  NBC News
  3. Daily pill doubles survival time for pancreatic cancer patients  BBC
  4. ‘Landmark’ pancreatic cancer drug keeps patients alive for twice as long  The Washington Post
  5. Experimental pancreatic cancer drug offers new hope in major trial  ABC News - Breaking News, Latest News and Videos

Want the full story? Read the original reporting

Read on statnews.com